Medsintez Plant took part in the Eurasian International Medical Forum

From May 20 to 22, the first Eurasian International Medical Forum was held in Ekaterinburg. The event was dedicated to the 80th anniversary of Victory in the Great Patriotic War. The Forum brought together over 1,000 participants and 250 experts from Russia, India, China and Belarus. Medsintez Plant took an active part in scientific program of the Forum and demonstrated its latest developments in the field of import-substituting drugs.

At the grand opening of the Forum, Tatiana Savinova, the Deputy Governor and Minister of Health of the Sverdlovsk Region, noted the importance of such events for the professional growth of medical specialists and the exchange of experience. She also emphasized the positive dynamics in reducing mortality in the region and called on medical organizations to continue working in this area.

The Forum was dedicated to the new national project «Long and Active Life». The exhibition presented more than 1,000 units of modern medical equipment and organized about 20 thematic sections with the participation of leading experts. In addition, on the first day of the Forum, several significant agreements were signed, including Memorandum of Understanding between the Indian Business Council and the Association of Medical and Pharmaceutical Manufacturers of the Sverdlovsk Region, whose primary pharmaceutical enterprise is Medsintez Plant.

The booth of Medsintez Plant attracted great interest of the exhibition visitors. Among the new products presented was the world's first recombinant human albumin drug for the treatment of type 2 diabetes Semaglutide (analogue to Ozempic), as well as drugs for the treatment of infertility – recombinant human chorionic gonadotropin (HCG) and Cetrorelix. Triazavirin, Russian antiviral drug, effective for treatment of influenza, acute respiratory viral infections and COVID-19; the range of Rosinsulin drugs; Primapur, the first Russian follitropin alpha drug for human infertility treatment, and the first Russian species-specific veterinary insulins Vinsuvet were also presented at the exhibit booth.

Last year, the plant launched the full production cycle of the world's first registered recombinant human albumin drug, which is identical in its properties to the natural one, but eliminates the risk of contamination by viruses during production. This allows for the large-scale manufacturing of the drug, without regard to the donor resources.

Thanks to the drug Primapur used in the IVF procedure, more than 20 thousand children have already been born in Russia. The company continues to develop hormonal drugs such as HCG and Cetrorelix for the reproductive medicine in order to create a full line of such products and ensure the drug safety of the country.

Moreover, with the support of the Industrial Development Fund, Medsintez Plant is preparing to launch the Semaglutide drug for the treatment of type 2 diabetes. The plant also launched the production of veterinary insulins Vinsuvet separately for cats and dogs. The domestic production of these drugs will help to fill the shortage of similar drugs after the cessation of import supplies.

The company plays an important role in the fight against epidemics by producing Triazavirin, an original Russian drug with proven direct antiviral activity against a wide range of RNA-containing viruses. Triazavirin is included in the federal clinical recommendations of the Ministry of Health of Russia for treatment of influenza and ARVI in adults and this is the only direct-acting antiviral drug approved for the prevention of COVID-19.

In addition, Triazavirin has demonstrated a high efficacy, a good safety and tolerability profile based on the results of clinical trials of the pediatric form of the drug at a dosage of 100 mg for the treatment of acute respiratory viral infections in children aged 6 to 17 years.

Since 2009, Medsintez Plant has been providing sustainable drug safety for Russian patients with diabetes. The company produces the range of Rosinsulin drugs from its own substances, meeting 100% of Russia’s need for insulin drugs.

Medsintez Plant LLC is one of the leading enterprises of the Sverdlovsk Region in the field of healthcare. The plant is included in the list of systemic companies of Russia and is a driver of development of the pharmaceutical industry in the Urals. For 20 years, ensuring national drug safety has been a priority for Medsintez Plant. In 2025, the plant received the status of National Champion.